Related Experiment Video
Updated: Jan 21, 2026

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
The Suppression of Prolactin is required for the Treatment of Advanced Prostate Cancer
1Department of Oncology and Diagnostic Sciences; University of Maryland School of Dentistry; and the University of Maryland Greenebaum Comprehensive Cancer Center, USA.
Abstract:
Androgen-independent advanced prostate cancer is a terminal malignancy that generally results in death within five years. Its cause has been unknown, and a treatment did not exist. Prevailing views have mistakenly implicated impaired androgen receptor activity in the development of androgen-independent malignancy; which has deterred the existence of an effective treatment. Instead, recent reports have provided evidence that prolactin promotes the development and progression of androgen-independent malignancy; which follows androgen ablation treatment for androgen-dependent prostate cancer. That relationship dictates that a treatment for advanced prostate cancer should suppress the concentration plasma prolactin. This has been achieved with cabergoline (dopamine agonist; Dostinex) treatment of a patient that resulted in 88% decreased plasma prolactin, and terminated the malignancy. That likely represents the first effective treatment for advanced prostate cancer. It remains to establish if this treatment will be successful for other patients with advanced prostate cancer.
Insights
A novel treatment targeting prolactin, a key driver of advanced prostate cancer, has shown promising results. Cabergoline therapy significantly reduced prolactin levels and terminated malignancy in one patient, offering hope for effective prostate cancer treatment.
Area of Science:
- Oncology
- Endocrinology
Background:
- Androgen-independent advanced prostate cancer is a fatal malignancy with no effective treatments.
- Misconceptions regarding androgen receptor activity have hindered treatment development.
- Emerging evidence links prolactin to the progression of androgen-independent prostate cancer.
Purpose of the Study:
- To investigate the role of prolactin in advanced prostate cancer.
- To determine if suppressing prolactin can be an effective treatment strategy.
Main Methods:
- Administered cabergoline (a dopamine agonist) to a patient with advanced prostate cancer.
- Monitored plasma prolactin levels before and during treatment.
Main Results:
- Cabergoline treatment led to an 88% decrease in plasma prolactin.
- The malignancy was terminated in the treated patient.
- This suggests a potential new therapeutic approach.
Conclusions:
- Prolactin plays a crucial role in advanced prostate cancer progression.
- Suppressing prolactin with cabergoline may offer the first effective treatment for this condition.
- Further studies are needed to confirm efficacy in a broader patient population.
Related Concept Videos
Treatment Resistant Cancers
Requirements for Human Life
Oxygen
Atmospheric air is only about 20 percent oxygen, but that oxygen is a key component of the chemical reactions that keep the body alive, including the reactions that produce ATP. Brain cells are susceptible to a lack of oxygen because they require a...
Proteins: Dietary Sources and Requirements
Oxygen Requirements and Growth Patterns
Energy-requiring Steps of Glycolysis
Carbohydrates: Dietary Sources and Requirements

